Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Attorneys representing ovarian cancer victims in lawsuits against Johnson & Johnson (NYSE:JNJ) are advocating for the Ending Corporate Bankruptcy Abuse Act (ECBA). This bipartisan legislation aims to prevent solvent companies from using the 'Texas Two-Step' bankruptcy process to avoid lawsuit liabilities. J&J has twice attempted to use this tactic to resolve talc-related ovarian cancer claims.
The ECBA would treat such bankruptcy filings as bad faith and prohibit stays of litigation against non-bankrupt affiliates. Co-lead counsels Michelle Parfitt and Leigh O'Dell emphasize the legislation's importance in protecting justice and fairness. They highlight the financial devastation faced by victims, with average medical costs exceeding $220,000, while J&J earned over $83 billion in 2023.
The legislation has support from both Democratic and Republican lawmakers, who criticize the abuse of the bankruptcy system by wealthy corporations at the expense of harmed individuals. There are currently over 57,000 pending cases in the J&J Talcum Powder Products Liability Litigation.
Johnson & Johnson (NYSE: JNJ) announced promising results from the Phase 2 UNITY study of nipocalimab for treating pregnant individuals at risk of early onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN). The study, published in The New England Journal of Medicine, met its primary endpoint with 54% of participants achieving live birth at or after 32 weeks without needing intrauterine transfusion (IUT).
Key findings include:
- Nipocalimab delayed or prevented severe fetal anemia
- Reduced need for IUTs in high-risk pregnancies
- 92% live births in study pregnancies vs. 38% in qualifying pregnancies
- No incidences of fetal hydrops in study pregnancies
The AZALEA Phase 3 study is currently enrolling patients to further assess nipocalimab's efficacy and safety in severe HDFN treatment.
Johnson & Johnson (NYSE:JNJ) announced FDA approval for DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. The approval is based on the Phase 3 PERSEUS study, which showed:
1. 60% reduction in risk of disease progression or death with D-VRd compared to VRd
2. Improved minimal residual disease negativity rates: 57.5% vs 32.5%
3. Deeper responses at the end of consolidation
This quadruplet therapy offers a new frontline treatment option that may significantly improve outcomes for patients. The safety profile was consistent with known profiles for DARZALEX FASPRO® and VRd.
Johnson & Johnson (NYSE: JNJ) has announced its participation in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5th, at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President and WorldWide Chairman of MedTech, will represent the company in a session scheduled for 11:00 am (Eastern Time).
The event will feature a live audio webcast accessible to investors and interested parties through the Johnson & Johnson website at www.investor.jnj.com. An audio replay will be available approximately 48 hours after the webcast concludes. This conference provides an opportunity for JNJ to showcase its latest developments and strategies in the healthcare sector.
Johnson & Johnson (NYSE: JNJ) faces significant challenges in its third attempt to use the 'Texas Two-Step' bankruptcy strategy to manage talc-related liabilities. The U.S. Court of Appeals for the 3rd Circuit recently rejected J&J's previous bankruptcy attempt, deeming it filed in bad faith. Additionally, bipartisan legislation, the Ending Corporate Bankruptcy Abuse Act (ECBA) of 2024, has been introduced to ban such maneuvers.
J&J faces a July 26 deadline for talc claimants to vote on a third bankruptcy attempt. Critics argue the proposed compensation unfairly shortchanges victims. The company needs 75% approval to proceed with another Texas Two-Step filing in Texas. Lawyers representing ovarian cancer victims urge J&J to abandon this strategy and provide fair compensation.
Today at 5pm ET marks the final deadline for ovarian cancer victims to vote on Johnson & Johnson's (NYSE: JNJ) $8 billion talcum powder settlement. The plan, with a net present value of $6.475 billion, aims to compensate current and future claimants harmed by J&J's talc products. Ovarian cancer claimants are expected to receive $75,000 to $150,000 each on average.
The Ad Hoc Group of Counsel, representing over 77,500 individuals, urges all affected to vote YES, emphasizing that 75% approval is needed. They refute claims by opposing law firms, stating that the settlement offers a fair and timely resolution compared to prolonged litigation. Claimants can vote at www.OfficialTalcClaims.com or by calling 1-888-431-4056.
Johnson & Johnson (NYSE: JNJ) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at the New York Marriott Marquis. Joaquin Duato, Chairman and CEO, and John Reed, Executive VP of Innovative Medicine R&D, will represent the company in a session scheduled for 10:45 am ET.
A live audio webcast of the session will be available on Johnson & Johnson's investor website. Investors and interested parties can access the webcast at www.investor.jnj.com. An audio replay will be available approximately 48 hours after the event.
Lawyers representing ovarian cancer victims are urging a NO vote on Johnson & Johnson's (NYSE:JNJ) latest $6.5 billion bankruptcy settlement plan. They claim J&J is misleading potential claimants and attempting to secure approvals from individuals without documented ovarian cancer diagnoses. The attorneys argue this strategy could reduce payments to legitimate victims who have incurred losses of $500,000 or more.
The deadline for voting on the bankruptcy proposal is July 26, 2024. Opponents of the plan note that approval would eliminate rights to a jury trial for current and future victims. Since 2016, juries have awarded over $5.4 billion in damages to ovarian cancer claimants, although this amount has been reduced in subsequent court proceedings.
Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking approval of SPRAVATO® (esketamine) as a monotherapy for adults with treatment-resistant depression (TRD). This submission is based on positive results from the Phase 4 TRD4005 study, which showed rapid improvement in depressive symptoms as early as 24 hours after the first dose, sustained through at least 4 weeks of treatment. The safety profile was consistent with existing clinical data.
SPRAVATO® is currently approved in combination with an oral antidepressant for TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. It has been approved in 77 countries and administered to over 100,000 people worldwide. This new application aims to expand its use as a standalone treatment for TRD, potentially offering a new option for patients who have not responded adequately to multiple oral antidepressants.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.24 per share for the third quarter of 2024. The dividend will be payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is also set for August 27, 2024. This announcement demonstrates JNJ's commitment to returning value to shareholders through consistent dividend payments.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
